Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15130506 | 0.83 | DCUN1D1 (0.56) | NR1H2NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL15119919 | 0.81 | ALPL (0.56) | NR1H2NR1H3MEN1KMT2ACYP1A2 | |
| SCHEMBL25957508 | 0.79 | KDM4E (0.61) | NR1H2NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL15117057 | 0.77 | DCUN1D1 (0.63) | NR1H2NR1H3ALDH1A1CYP1A2DCUN1D1 | |
| SCHEMBL8963341 | 0.74 | TSHR (0.49) | KMT2AALDH1A1ADORA3LMNAHPGDS | |
| SCHEMBL28694981 | 0.74 | MAPT (0.49) | MEN1KMT2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL2629349 | 0.74 | NR1H2 (0.61) | NR1H2NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL12862531 | 0.73 | NR1H2 (0.50) | NR1H2NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL17336879 | 0.72 | MEN1 (0.53) | NR1H2NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL666693 | 0.71 | NR1H2 (1.00) | NR1H2NR1H3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994913-B2 | Methods and compositions for detecting and treating drug resistant AKT mutant | GENENTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170065588-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140031259-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | PIK3CA, PIK3C2B, PIK3CG | NR1H2 1751/4885NR1H3 1368/4885MEN1 2170/4885 |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | PIK3R2, PIK3R1, AKT2 | NR1H2 2972/4885NR1H3 2883/4885MEN1 2621/4885 |
| US-20170065588-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | TP53, TSG101, CD44 | NR1H2 3527/4885NR1H3 3396/4885MEN1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.